Challenges for chemotherapy in ovarian cancer
Challenges for chemotherapy in ovarian cancer
复制标题
DOI：
10.1093/annonc/mdj978
复制
发表时间：
2006-01-01
影响因子：
50.5
通讯作者：
Ozols, R. F.
中科院分区：
文献类型：
--
作者：
Ozols, R. F.
背景：卵巢癌的治疗采用手术后联合紫杉醇加卡铂化疗。为了改善结果，临床试验正在评估以下策略：维持治疗;腹膜内给药;新的组合;新的细胞毒素;复发性疾病的联合化疗;和分子靶向治疗。结果：联合化疗方案对复发性卵巢癌的疗效上级单药治疗。分子靶向治疗已在既往接受过治疗的患者中产生了客观反应。任何类型的维持治疗都没有显示出延长生存期。腹膜内治疗已导致改善生存率与相当大的毒性在小容量III期diseases.Conclusions患者：许多新的临床策略正在评估卵巢癌，有可能改善预后相比，标准治疗。
Background: Ovarian cancer is treated with surgery followed by combination chemotherapy with paclitaxel plus carboplatin. In an effort to improve outcomes, clinical trials are evaluating the following strategies: maintenance therapy; intraperitoneal drug administration; new combinations; novel cytotoxics; combination chemotherapy for recurrent disease; and molecular-targeted therapies.Patients and methods: Clinical trials evaluating the above strategies are being performed in ovarian cancer in patients with: (1) previously untreated advanced ovarian cancer; (2) platinum-sensitive recurrent disease; and (3) platinum-resistant recurrent disease.Results: Combination chemotherapy regimens are superior to single-agent therapy in recurrent ovarian cancer. Molecular-targeted therapy has produced objective responses in previously treated patients. Maintenance therapy of any type has not been shown to prolong survival. Intraperitoneal therapy has resulted in improved survival with considerable toxicity in patients with small-volume stage III disease.Conclusions: Numerous novel clinical strategies are being evaluated in ovarian cancers that have the potential to improve outcomes compared to standard therapy.